Vitalik Buterin’s Layer-2 Revolution: Ethereum Rollups Set for Massive Speed Boost

Ethereum's co-founder drops bombshell upgrade that could transform blockchain scalability overnight.

The Need for Speed

Vitalik Buterin's latest proposal targets Layer-2 rollups with performance enhancements that promise to slash transaction times and gas fees. The upgrade focuses on optimizing data compression and state management—critical bottlenecks that have plagued Ethereum's scaling solutions.

Rollup Renaissance

This isn't just incremental improvement—it's architectural overhaul. Buterin's plan rethinks how rollups handle computation and storage, potentially unlocking throughput levels previously thought impossible on Ethereum's current infrastructure.

Market Implications

Faster rollups mean cheaper DeFi transactions, smoother NFT minting, and finally—maybe—mainstream adoption that doesn't require taking out a second mortgage for gas fees. Because nothing says 'financial revolution' like paying $50 to swap $100 of tokens.

The Ethereum ecosystem holds its breath as Buterin's vision could either cement its dominance or become another 'coming soon' feature in crypto's graveyard of promised solutions.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The pharmaceutical company also cut its full-year revenue forecast for the fourth time this year. This is even as Novo Nordisk’s third-quarter 2025 earnings results released today showed numbers that miss Wall Street’s projections.

Novo Nordisk’s Is Here — Incoming Eli Lilly Deal?

According to Reuters, Novo Nordisk’s arrangement relates to semaglutide, the active ingredient in its flagship weight-loss drug Wegovy and diabetes injection Ozempic. The announcement comes as media reports have previously suggested that Novo Nordisk and its arch-rival, Eli Lilly (LLY), are expected to enter a deal with the TRUMP administration to cut the prices of their obesity drugs, with the lowest dose expected to cost $149 per month.

For Eli Lilly, this price deal is anticipated for its top-selling medications Zepbound and Mounjaro, which are used to manage weight and diabetes, respectively. These medications come with a list price that tops $1000, although U.S. consumers usually buy them at lower prices, depending on their health insurance plans and the discounts they can get.

Is the Medicare Deal Beneficial for Novo Nordisk?

The deals are expected in exchange for the admission of the drugmaker’s medications into the U.S. government-funded Medicare health insurance program. About 69 million Americans were enrolled in the program as of June 2025, according to the U.S. Centers for Medicare and Medicaid Services.

Usually, pharma companies getting their medications into the program suggest additional revenue sources. However, analysts are concerned about the impact of the price deal for Novo Nordisk due to the nature of the price cut.

Reacting to the news of the potential deal for Novo Nordisk and Eli Lilly, UBS’s (UBS) equity research team noted that the proposed $149/month price is likely to be received negatively because it marks a significant discount compared with obesity drug pricing in markets outside the U.S.

The deal comes at a time the Danish drugmaker is facing several headwinds as it plans to cut about 9,000 jobs and is battling it out with Pfizer (PFE) to take control of obesity-focused biotech firm Metsera (MTSR).

Is Novo Nordisk a Buy, Sell, or Hold?

On Wall Street, Novo Nordisk’s shares currently have a Moderate Buy rating, according to TipRanks. This is based on five Buys, two Holds, and one Sell assigned by eight analysts over the past three months.

However, the average NVO price target of $60.50 indicates about a 30% upswing from the current trading level.